ArticleJAMA2023
Development of Duffy Null-Specific Absolute Neutrophil Count Reference Ranges.
Article in JAMA, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Limited inclusion in clinical trials and access to poly (ADP-ribose) polymerase inhibitors in racial and ethnic minority patients with cancer: a narrative review.The oncologist · 2026Review
- Establishing Reference Intervals for White Blood Cell and Absolute Neutrophil Counts in Duffy Null Individuals.Hematology reports · 2026Article
- Challenges and Potential Solutions to Advance Global Cancer Drug Development.Therapeutic innovation & regulatory science · 2026Review
- Increasing Leukocyte and Neutrophil Count with Vitamin C Supplementation: A Case Report.Integrative medicine (Encinitas, Calif.) · 2026Article
- Blood cell ratio biomarkers of systemic inflammation in chronic obstructive pulmonary disease.Respiratory research · 2026Article
- Blood Cell Ratio Biomarkers of Non-type 2 Inflammation in Chronic Obstructive Pulmonary.Research square · 2026Article
- A Case of Duffy-Null-Associated Neutropenia in a Patient With Chronic Myeloid Leukemia.Case reports in hematology · 2026Article
- Article
- A paradigm shift in neutrophil adverse event grading: Why now?HemaSphere · 2025Article
- Medical haematology trial eligibility and the Duffy null-associated neutrophil count: A cross-sectional study.HemaSphere · 2025Article
- Management of Graves Disease With Co-Existing Duffy-Null Phenotype.JCEM case reports · 2025Article
- Characterization of the phenotypic consequences of the Duffy-null genotype.Blood advances · 2025Article
- Delayed neutrophil recovery following BCMA CAR-T therapy in Duffy-null myeloma does not impact severe infections or survival.Blood advances · 2025Article
- The Duffy Null Phenotype - Addressing a Source of Discrimination in Cancer Care.The New England journal of medicine · 2024Article
- Cancer Trial Eligibility and Therapy Modifications for Individuals With Duffy Null-Associated Neutrophil Count.JAMA network open · 2024Article
- Disparities in relapsed or refractory multiple myeloma: recommendations from an interprofessional consensus panel.Blood cancer journal · 2024Review
- Invisible Infrastructure in Haematology: Neutrophil Reference Ranges and the Duffy-null Phenotype.HemaSphere · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.